1. Home
  2. QD vs PHAT Comparison

QD vs PHAT Comparison

Compare QD & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qudian Inc. each representing one

QD

Qudian Inc. each representing one

HOLD

Current Price

$3.84

Market Cap

807.5M

Sector

Finance

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$14.66

Market Cap

942.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QD
PHAT
Founded
2014
2018
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
807.5M
942.6M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
QD
PHAT
Price
$3.84
$14.66
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$17.33
AVG Volume (30 Days)
310.9K
809.7K
Earning Date
11-24-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
2364.38
N/A
EPS
0.67
N/A
Revenue
$12,647,260.00
$147,190,000.00
Revenue This Year
N/A
$218.59
Revenue Next Year
N/A
$84.38
P/E Ratio
$6.13
N/A
Revenue Growth
N/A
460.30
52 Week Low
$2.04
$2.21
52 Week High
$5.08
$16.45

Technical Indicators

Market Signals
Indicator
QD
PHAT
Relative Strength Index (RSI) 31.11 52.94
Support Level $3.89 $14.12
Resistance Level $4.91 $16.45
Average True Range (ATR) 0.18 0.74
MACD -0.11 -0.11
Stochastic Oscillator 1.83 21.46

Price Performance

Historical Comparison
QD
PHAT

About QD Qudian Inc. each representing one

Qudian Inc is a consumer-oriented technology company engaged in the operation of online platforms to provide small consumer credit products in the People's Republic of China. It aims to empower financial institutions with its technological capabilities, help them improve marketing and operating efficiency, and enable financial institutions to efficiently connect their diversified financial products with scene traffic across the entire network It derives a majority of its revenue from the People's Republic of China.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: